Roche Holding is trading at CHF 360.60, up 3.26%, following a clinical trial collaboration agreement with Treeline Biosciences for a Phase I study in B-cell lymphomas. This collaboration will assess Treeline's BCL6 degrader TLN-121 with Roche's glofitamab and mosunetuzumab. The company also recently finalized an exclusive global licensing deal with Simcere for the experimental SIM0660 blood-cancer drug, involving a $75 million upfront payment and up to $1.53 billion in potential milestones.